Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting
By Lori Solomon HealthDay Reporter
FRIDAY, May 9, 2025 -- The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to a study published online May 1 in JAMA Ophthalmology.
Karoline E. Binder, M.D., from the Technical University of Munich, and colleagues assessed the incidence of IOI after intravitreal injection of aflibercept, 8 mg, in real-world practice. The analysis included 41 patients (23 with neovascular age-related macular degeneration and 18 with diabetic macular edema) who were treated with 136 intravitreal aflibercept, 8 mg, injections.
The researchers reported that five patients developed mild sterile IOI within one to three days after the intervention (incidence per injection, 3.7 percent; incidence per patient, 12 percent). Only one patient developed inflammation after the first dose, while the other four had prior exposure to aflibercept. All patients were treated with local anti-inflammatory therapy (topical or subconjunctival corticosteroids), while two patients received additional systemic oral corticosteroids. After IOI resolved, there was no reduction in best-corrected visual acuity.
"Although the IOI found in this series can be considered mild, careful evaluation of patient-associated risk factors and thorough patient education are warranted," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Prevalence, Incidence of Diabetic Retinal Disease Increased in Recent Years
TUESDAY, July 8, 2025 -- The prevalence and incidence of diabetic retinal disease (DRD) has increased in recent years, while the incidence of vision-threatening diabetic...
Risk for Postop Proliferative Vitreoretinopathy Lower With Cannabis Use
MONDAY, July 7, 2025 -- Patients undergoing retinal detachment (RD) repair with concomitant cannabis use have a lower risk for subsequent proliferative vitreoretinopathy (PVR) and...
GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
FRIDAY, June 6, 2025 -- For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.